(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2013 (10.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/067355 A1

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/US2012/063330

(22) **International Filing Date**:
2 November 2012 (02.11.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/555,848 4 November 2011 (04.11.2011) US

(71) **Applicant**: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **JENKINS, David** [US/US]; Novartis Institutes for BioMedical, Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LEI, Ming** [CN/US]; Novartis Institutes for BioMedical, Research, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US). **LOEW, Andreas** [DE/US]; Novartis Institutes for BioMedical, Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **ZHOU, Li** [US/US]; Novartis Institutes for BioMedical, Research, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) **Agent**: **SAGOO, Jasbir**; Novartis Institutes for BioMedical, Research, Inc., NIBR Patents, 250 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/067355 A1

(54) **Title**: LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6 (LRP6) - HALF LIFE EXTENDER CONSTRUCTS

(57) **Abstract**: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.